The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A (1997) Gastroenterology 112: 29-32 Considerations and challenges in defining optimal iron utilization in hemodialysis. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S, Dialysis Advisory Group of the American Society of Nephrology (2015) J Am Soc Nephrol 26: 1238-47 Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose. Derebail VK, Lacson EK, Kshirsagar AV, Key NS, Hogan SL, Hakim RM, Mooney A, Jani CM, Johnson C, Hu Y, Falk RJ, Lazarus JM (2014) J Am Soc Nephrol 25: 819-26 Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Babitt JL, Eisenga MF, Haase VH, Kshirsagar AV, Levin A, Locatelli F, Małyszko J, Swinkels DW, Tarng DC, Cheung M, Jadoul M, Winkelmayer WC, Drüeke TB, Conference Participants (2021) Kidney Int 99: 1280-1295 Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Gupta A, Lin V, Guss C, Pratt R, Ikizler TA, Besarab A (2015) Kidney Int 88: 1187-94 Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study Group (2013) Am J Kidney Dis 61: 759-66 Dialysis facility ownership and epoetin dosing in hemodialysis patients: a dialysis provider's perspective. Lazarus JM, Hakim RM (2007) Am J Kidney Dis 50: 366-70 Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology. Williams AW, Dwyer AC, Eddy AA, Fink JC, Jaber BL, Linas SL, Michael B, O'Hare AM, Schaefer HM, Shaffer RN, Trachtman H, Weiner DE, Falk AR, American Society of Nephrology Quality, and Patient Safety Task Force (2012) Clin J Am Soc Nephrol 7: 1664-72 MTHFR polymorphisms, dietary folate intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Shrubsole MJ, Gao YT, Cai Q, Shu XO, Dai Q, Hébert JR, Jin F, Zheng W (2004) Cancer Epidemiol Biomarkers Prev 13: 190-6 Is weekly iron and folic acid supplementation as effective as daily supplementation for decreasing incidence of anemia in adolescent girls? Perrin E, Rothman R, Coyne-Beasley T, Ford C, Bordley WC (2002) Arch Pediatr Adolesc Med 156: 128-30 Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M, Hakim RH (2009) Nephrol Dial Transplant 24: 919-25 Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Haase VH, Chertow GM, Block GA, Pergola PE, deGoma EM, Khawaja Z, Sharma A, Maroni BJ, McCullough PA (2019) Nephrol Dial Transplant 34: 90-99 Prevalence of daily medication adherence among children with sickle cell disease: a 1-year retrospective cohort analysis. Patel NG, Lindsey T, Strunk RC, DeBaun MR (2010) Pediatr Blood Cancer 55: 554-6 Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients. Rivara MB, Ikizler TA, Ellis CD, Mehrotra R, Himmelfarb J (2015) BMC Nephrol 16: 79 Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone. Katagiri D, Shibata M, Katsuki T, Masumoto S, Katsuma A, Minami E, Hoshino T, Inoue T, Tada M, Hinoshita F (2010) Clin Exp Nephrol 14: 501-5
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.